Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740452 | 0.89 | GPBAR1 (0.56) | GPBAR1PDGFRBPDGFRANPC1KDM4E | |
| SCHEMBL4742362 | 0.86 | KDM4E (0.45) | GPBAR1PDGFRBPDGFRAKDM4EAXL | |
| SCHEMBL4741381 | 0.82 | ELANE (0.45) | GPBAR1KDM4EAXLNR4A2 | |
| SCHEMBL3259682 | 0.81 | CSNK2A2 (0.47) | GPBAR1PDGFRBPDGFRAKDM4EAXL | |
| SCHEMBL4741886 | 0.79 | PDGFRB (0.60) | GPBAR1PDGFRBPDGFRANPC1MAOB | |
| SCHEMBL4741876 | 0.78 | GPBAR1 (0.68) | GPBAR1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4740926 | 0.78 | GPBAR1 (0.59) | GPBAR1PDGFRBPDGFRANPC1KDM4E | |
| SCHEMBL4742376 | 0.78 | GPBAR1 (0.56) | GPBAR1 | |
| SCHEMBL4741474 | 0.76 | GPBAR1 (0.69) | GPBAR1PDGFRBPDGFRANPC1KDM4E | |
| SCHEMBL24373427 | 0.74 | KDM4E (0.57) | NPC1KDM4EPLA2G2ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097976-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPR119, GPBAR1, LDLR | GPBAR1 2/4885PDGFRB 1505/4885PDGFRA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.